32 results about "Chondropathy" patented technology

Cells derived from postpartum tissue and methods for their isolation and induction to differentiate to cells of a chondrogenic or osteogenic phenotype are provided by the invention. The invention further provides cultures and compositions of the postpartum-derived cells and products related thereto. The postpartum-derived cells of the invention and products related thereto have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications, for example, in the treatment of bone and cartilage conditions.

The invention discloses a medicine which cures osteoarthritis and is a compound which is formed by combining (S)-ibuprofen and dextrosamine or the medicine salt thereof according to 1:3 of mass ratio. The (S)-ibuprofen and the dextrosamine are prepared into compound preparation. The characteristics of rapid drug effects and strong abirritation of the (S)-ibuprofen can be used for rapidly relieving symptoms on the one hand; on the other hand, the dextrosamine can defer cartilage degeneration process, repairs cartilage pathological changes, and prevents, even reverses the disease process. Meanwhile, the (S)-ibuprofen and the dextrosamine are prepared into the compound preparation, which can reduce the dose of single medicine and further reduce the toxic side effects. The compound preparation prepared by the (S)-ibuprofen and the dextrosamine of the invention becomes a new medicine which can cure the osteoarthritis.

The inventors of the present invention searched for a substance that is effective in treating a cartilage disorder, and as a result, found that, in an animal model of joint cartilage deficiency, an HMGB1 fragment peptide having a specific amino acid sequence exhibits the effect of reproducing a healthy cartilage tissue including a hyaline cartilage. Based on this finding, the present invention provides a pharmaceutical composition that contains the specific HMGB1 fragment peptide and that is for preventing and / or treating a cartilage disorder.

This invention provides a method for administration of an effective amount of RANKL-binding molecules that act on prechondrocytes and / or mesenchymal stem cells, accelerate cartilage differentiation, proliferation, and maturation of such cells, enhance chondrocyte differentiation, and induce chondrocyte proliferation to induce chondrocyte proliferation and differentiation or increase cartilage matrix production and a pharmaceutical composition used for inducing chondrocyte proliferation and differentiation or increasing cartilage matrix production. The pharmaceutical composition used for treatment or prevention of a chondropathies comprises, as an active ingredient, a compound that acts on prechondrocytes and / or mesenchymal stem cells and induces at least one of the following: (a) acceleration of prechondrocyte and / or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and / or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and / or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; (e) chondrocyte proliferation; and (f) increased production of the cartilage matrix.

The invention is relevant to chemistry of organic compounds, pharmacology and medicine, and is related to prevention and treatment of musculoskeletal diseases in human and animals associated with the disorder of bone and / or cartilage metabolism, particularly with such musculoskeletal diseases as osteoporosis, osteoarthritis and osteochondrosis, using a new salt form of 2,2-dimethyl-6-((4-((3,4,5-trimethoxyphenyl)amino)-1,3,5-triazine-2-yl)amino)-2H-pyrido[3,2-b][1,4]oxazine-3(4H)-one. A salt of this compound with 4-methylbenzenesulfonic acidincluding its hydrates, solvates and polymorphic modifications of the salt, hydrates and solvates is featured with acceptable pharmacokinetic parameters and increased efficiency in the inhibition of Src-family kinases and Syk kinase, as well as other therapeutically significant kinases. This invention also covers pharmaceutical compositions containing therapeutically effective amount of the salt according to the invention.